Date Published:
2019 12 20

Publication Type:
Journal Article

Authors:

A.S. Devanathan
J.R. Pirone
R. Akkina
L. Remling-Mulder
P. Luciw
L. Adamson
V. Garcia
M. Kovarova
N.R. White
A.P. Schauer
K. Blake
C. Sykes
E.M. Burgunder
N. Srinivas
E.P. Rosen
A.D.M. Kashuba

Secondary:
Antimicrob Agents Chemother

Volume:
64

Issue:
1

PMID:
31611355

URL:
https://pubmed.ncbi.nlm.nih.gov/31611355

DOI:
10.1128/AAC.01639-19

Keywords:
Animals;Anti-HIV Agents;Anti-Retroviral Agents;Atazanavir Sulfate;Emtricitabine;Female;HIV Infections;Humans;In Vitro Techniques;Maraviroc;Mice;Raltegravir Potassium;Tenofovir

Abstract:
<p>For HIV cure strategies like "kick and kill" to succeed, antiretroviral (ARV) drugs must reach effective concentrations in putative viral reservoirs. We characterize penetration of six ARVs in three preclinical animal models and humans. We found that standard dosing strategies in preclinical species closely mimicked tissue concentrations in humans for some, but not all, ARVs. These results have implications for interpreting HIV treatment, prevention, or cure interventions between preclinical and clinical models.</p>